SmartBalloon Medical Technology：Related Service

Kexing Biopharm's Independently Developed Ophthalmic Innovative Drug GB10 Receives Clinical Trial Approval

admin2026-01-09

Recently, GB10 Injection—a high-concentration ophthalmic-specific protein formulation of an anti-VEGF/Ang-2 dual-target antibody independently developed by the company and holding global intellectual property rights—has officially received the...